Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Market Access Granted in Italy for PIXUVRI®

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
Access granted by AIFA for the aggressive non-Hodgkin lymphoma treatment.

Cell Therapeutics, Inc. (CTI) has announced that the Company has been granted market access by the Italian Medicines Agency (AIFA) for the medicinal product PIXUVRI® (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy).

Pixantrone has been classified by AIFA for use in hospitals and additional details on the pricing and reimbursement conditions for PIXUVRI in Italy will be provided coincident with the publication of the "Determina" of AIFA in the Official Gazette, which is expected to take 6 to 8 weeks.

In May 2012, the European Commission (EC) granted conditional marketing authorization in the European Union (E.U.) for PIXUVRI as a monotherapy for adult patients with multiply relapsed or refractory aggressive B-cell NHL based on the results of the EXTEND, or PIX301, pivotal randomized Phase 3 clinical trial.

PIXUVRI was made available to patients in eight countries in the European Union in the fourth quarter of 2012, and some patients in other countries have already started to receive the treatment.

Prior to the approval of PIXUVRI in the E.U., there were no approved agents or standard of care in this disease.

The PIX301 trial was designed utilizing agents in the comparator arm that have anti-tumor activity in relapsed disease and are typically employed as palliative therapy for these patients.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PIXUVRI® Receives Positive Final Appraisal Determination from NICE
PIXUVRI deemed cost effective for patients with multiply relapsed or refractory aggressive b-cell non-Hodgkin lymphoma (NHL).
Monday, January 06, 2014
CTI and GKV-SV Reach Agreement on Pricing of PIXUVRI® (pixantrone) in Germany
Decision applies to patients with aggressive B-cell non-Hodgkin lymphoma who have failed two or three prior lines of therapy.
Wednesday, December 04, 2013
CTI OPAXIO™ Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Randomized front line trial utilizing tumor genomic profiling tests OPAXIO plus radiation therapy compared to current standard of care of radiation with temozolamide in high risk patients with glioblastoma multiforme.
Tuesday, October 09, 2012
Cell Therapeutics Appoints New Chief Medical Officer
Experienced Industry Executive, Steven E. Benner M.D., M.H.S., to lead cancer drug development.
Tuesday, June 19, 2012
CTI Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor
Phase 3 study in patients with myelofibrosis and low platelet counts targeted to start in Q4-2012.
Monday, June 04, 2012
CTI Enters into Agreement to Acquire Pacritinib
Reported lack of blood and platelet side effects provides attractive regulatory and commercial profile over other JAK inhibitors.
Friday, April 20, 2012
FDA's ODAC to Review Resubmitted Pixantrone NDA on February 9, 2012
ODAC will review resubmitted NDA for the treatment of relapsed or refractory aggressive NHL.
Monday, February 06, 2012
CTI Withdraws New Drug Application for Pixuvri™
The company plans to resubmit the application in 2012.
Monday, January 30, 2012
CTI Signs Long-Term Manufacturing Agreement for Pixantrone with NerPharMa
CTI plans marketing authorization application filing in Europe this year.
Wednesday, July 14, 2010
Italian Medicines Agency Approves NerPharMa to Manufacture CTI’s Drug Pixantrone in European Union
CTI is now preparing a Marketing Authorization Application in the European Union for pixantrone to treat non-Hodgkin's lymphoma.
Tuesday, June 15, 2010
Genes Identified that Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin
Systems Medicine presents data from a preclinical study that identifies potential clinical trial strategies for personalized approach to cancer treatment.
Wednesday, April 22, 2009
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!